Tenax Therapeutics to Participate in Upcoming Investor Conferences

Company Overview - Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company focused on developing novel cardiopulmonary therapies using clinical insights [3] - The company owns global rights to develop and commercialize levosimendan, targeting the treatment of PH-HFpEF, the most prevalent form of pulmonary hypertension, for which no product has been approved to date [3] - Tenax Therapeutics' common stock is listed on The Nasdaq Stock Market LLC under the symbol "TENX" [3] Upcoming Events - The company will present at the 8th Annual Evercore Healthcare Conference on December 2, 2025, at 4:15 p.m. ET, featuring a fireside chat with Chris Giordano, President & CEO, and Stuart Rich, M.D., Chief Medical Officer [1] - Additionally, Tenax Therapeutics will participate in the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025, at 11:30 a.m. ET, also in a fireside chat format [2] - Live and archived webcasts of these presentations will be accessible from the company's investor relations webpage [2]